REVB Key Statistics, Chart & Performance
The current stock price of REVB is 1.075 USD. In the past month the price increased by 1.92%. In the past year, price decreased by -93.87%.
REVB Latest News, Press Relases and Analysis
REVB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.61 | 394.32B | ||
| AMGN | AMGEN INC | 14.47 | 170.36B | ||
| GILD | GILEAD SCIENCES INC | 14.64 | 148.81B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.18 | 110.91B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.85 | 74.96B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 803.2 | 54.12B | ||
| INSM | INSMED INC | N/A | 41.65B | ||
| NTRA | NATERA INC | N/A | 32.67B | ||
| BIIB | BIOGEN INC | 10.43 | 25.62B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.27 | 20.76B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.26B | ||
| INCY | INCYTE CORP | 14.83 | 18.69B |
Related stock screener links
About REVB
Company Profile
Revelation Biosciences, Inc. is a clinical-stage life sciences company, which focuses on the development of immunologic-based therapies for the prevention and treatment of disease. The company is headquartered in San Diego, California and currently employs 8 full-time employees. The company went IPO on 2020-10-08. The firm's product candidates are based on the Gemini formulation of phosphorylated hexaacyl disaccharide (PHAD). The firm has multiple ongoing programs to evaluate Gemini, including GEM-AKI as a prevention of acute kidney injury (AKI), GEM-CKD as a treatment for chronic kidney disease (CKD), and GEM-PSI as a prevention of post-surgical infection (PSI). The Gemini-AKI program is being developed as a potential therapy for the prevention of AKI due to external stress or insult, such as surgical procedure and chemotherapy toxicity. GEM-PSI is being developed as a potential therapy for the prevention or treatment of healthcare-associated bacterial infections, including post-surgical infection, post-burn infection, urinary tract infection, sepsis, and antibiotic-resistant infection.
Company Info
REVELATION BIOSCIENCES INC
4660 Lajolla Village Drive, Suite 100
San Diego CALIFORNIA US
Employees: 9
Phone: 16508003717
REVELATION BIOSCIENCES INC / REVB FAQ
Can you describe the business of REVELATION BIOSCIENCES INC?
Revelation Biosciences, Inc. is a clinical-stage life sciences company, which focuses on the development of immunologic-based therapies for the prevention and treatment of disease. The company is headquartered in San Diego, California and currently employs 8 full-time employees. The company went IPO on 2020-10-08. The firm's product candidates are based on the Gemini formulation of phosphorylated hexaacyl disaccharide (PHAD). The firm has multiple ongoing programs to evaluate Gemini, including GEM-AKI as a prevention of acute kidney injury (AKI), GEM-CKD as a treatment for chronic kidney disease (CKD), and GEM-PSI as a prevention of post-surgical infection (PSI). The Gemini-AKI program is being developed as a potential therapy for the prevention of AKI due to external stress or insult, such as surgical procedure and chemotherapy toxicity. GEM-PSI is being developed as a potential therapy for the prevention or treatment of healthcare-associated bacterial infections, including post-surgical infection, post-burn infection, urinary tract infection, sepsis, and antibiotic-resistant infection.
What is the stock price of REVELATION BIOSCIENCES INC today?
The current stock price of REVB is 1.075 USD. The price increased by 1.42% in the last trading session.
Does REVB stock pay dividends?
REVB does not pay a dividend.
What is the ChartMill technical and fundamental rating of REVB stock?
REVB has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the next earnings date for REVB stock?
REVELATION BIOSCIENCES INC (REVB) will report earnings on 2026-03-04, after the market close.
Can you provide the ownership details for REVB stock?
You can find the ownership structure of REVELATION BIOSCIENCES INC (REVB) on the Ownership tab.
REVB Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to REVB. When comparing the yearly performance of all stocks, REVB is a bad performer in the overall market: 98.57% of all stocks are doing better.
REVB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to REVB. REVB has a great financial health rating, but its profitability evaluates not so good.
REVB Financial Highlights
Over the last trailing twelve months REVB reported a non-GAAP Earnings per Share(EPS) of -30.05. The EPS increased by 96.26% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -109.52% | ||
| ROE | -127.98% | ||
| Debt/Equity | 0 |
REVB Forecast & Estimates
7 analysts have analysed REVB and the average price target is 21.68 USD. This implies a price increase of 1916.28% is expected in the next year compared to the current price of 1.075.